Follow this organization
[ via
] [?]
Institute for Hepatitis and Virus Research
The Institute for Hepatitis and Virus Research (IHVR) is an independent nonprofit research institute established in 2003 by the Hepatitis B Foundation to conduct discovery research and foster translational biotechnology.
The IHVR, and the facility in which it operates, offers a unique and exceptional opportunity to bring scientists together from commercial, academic, and other nonprofit institutions to pursue common research themes in an environment conducive to interaction, collaboration and focus.
Our small but dedicated group of scientists has an impressive record of research results with direct translational applications, including therapeutic, biomarker, and diagnostic technologies relevant to Hepatitis B and C and other viral diseases, cancer, cirrhosis, fibrosis, and immune system modulation.
The IHVR has been integral in the formation of numerous spin-out ventures based on our technologies. Our licensing philosophy centers on recognizing the needs of commercial partners and reducing the obstacles to reaching mutually beneficial agreements. Our goal is to help get our innovations to those who will benefit from them as quickly as possible. Please contact Ethan Byler at 215-589-6426 or visit our website (www.ihvr.org) to learn more.
Innovations (13):
- 2-Amino-2,7dideoxy-alpha-D-glycero-D-gluco-heptopyranosyl Inhibitors of Positive Sense Single Stranded RNA Envelope Viruses (15 FEB 09)
- Inhibitors of Hepatitis B Virus (15 FEB 09)
- Compositions for oral administration for the treatment of interferon-responsive disorders (15 FEB 09)
- 7-(2-Chloro-6-fluoro-phenyl)-5-(4-chloro-phenyl)-4,5,6,7-tetrahydro-tetrazolo[1,5-a]pyrimidine and Related Compounds Inhibitors of Secretion of Hepatitis B Virus Antigens (15 FEB 09)
- Iminosugar Compounds with Antiflavirus activity (15 FEB 09)
- Novel imino sugar derivatives demonstrate potential antiviral activity and reduced toxicity (15 FEB 09)
- Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent (15 FEB 09)
- Method of inhibiting hepatitis B virus (15 FEB 09)
- Inhibition of membrane-associated viral replication (15 FEB 09)
- Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections (15 FEB 09)
Communities (0):
Institute for Hepatitis and Virus Research isn't a member of any communities.
|
Institute Administrator Innovations (11) |
|---|
ProfileFind more innovations
